192 related articles for article (PubMed ID: 31132887)
1. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.
Liu TH; Shao YY; Lu LC; Shen YC; Hsu C; Lin ZZ; Hsu CH; Cheng AL
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):615-621. PubMed ID: 31132887
[No Abstract] [Full Text] [Related]
2. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
3. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
4. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
6. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
7. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment including targeted therapy for advanced hepatocellular carcinoma.
Lin J; Wu L; Bai X; Xie Y; Wang A; Zhang H; Yang X; Wan X; Lu X; Sang X; Zhao H
Oncotarget; 2016 Oct; 7(43):71036-71051. PubMed ID: 27626176
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Bolondi L; Burroughs A; Dufour JF; Galle PR; Mazzaferro V; Piscaglia F; Raoul JL; Sangro B
Semin Liver Dis; 2012 Nov; 32(4):348-59. PubMed ID: 23397536
[TBL] [Abstract][Full Text] [Related]
10. Postoperative therapy options for hepatocellular carcinoma.
Zhong JH; Ma L; Li LQ
Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
Tsochatzis EA; Germani G; Burroughs AK
Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization of hepatocellular carcinoma--agents and drugs: an overview. Part 2.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 Jun; 10(6):799-810. PubMed ID: 23679932
[TBL] [Abstract][Full Text] [Related]
13. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
Allard MA; Sebagh M; Ruiz A; Guettier C; Paule B; Vibert E; Cunha AS; Cherqui D; Samuel D; Bismuth H; Castaing D; Adam R
J Hepatol; 2015 Jul; 63(1):83-92. PubMed ID: 25646884
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
15. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
16. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma.
Reidy DL; Schwartz JD
Anticancer Drugs; 2004 Jun; 15(5):427-37. PubMed ID: 15166616
[TBL] [Abstract][Full Text] [Related]
17. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
18. The role of molecular enrichment on future therapies in hepatocellular carcinoma.
Nault JC; Galle PR; Marquardt JU
J Hepatol; 2018 Jul; 69(1):237-247. PubMed ID: 29505843
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
Gao Q; Wang XY; Zhou J; Fan J
Nat Rev Clin Oncol; 2015 Jan; 12(1):10. PubMed ID: 25421283
[No Abstract] [Full Text] [Related]
20. Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.
Chan SL; Yeo W
World J Gastroenterol; 2014 Mar; 20(12):3135-45. PubMed ID: 24696599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
